{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:49:23Z","timestamp":1791791363486,"version":"4.3.4"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Wales aims to achieve the World Health Organisation goal of eliminating hepatitis C (HCV) as a public health threat by 2030, with micro\u2010elimination in prisons identified as a key target. In January 2022, HMP Berwyn, the largest prison in the United Kingdom, introduced a multi\u2010disciplinary blood borne virus (BBV) team and a streamlined testing and treatment pathway incorporating opt\u2010out testing, peer support, point\u2010of\u2010care viral load testing and pharmacist\u2010led prescribing. This service evaluation describes implementation of the pathway and its outcomes. Data relating to testing and treatment were collected between January 2023 and December 2024. In Welsh prisons micro\u2010elimination of HCV is defined as 100% of the population being offered a test, over 90% accepting testing and over 90% of those testing positive starting treatment. When micro\u2010elimination was first achieved in September 2023, the prison population was 2004. All prisoners had been offered HCV testing in the preceding 12\u2009months and 1915 (95.6%) accepted testing. Twenty\u2010seven men tested HCV PCR positive in the preceding 6\u2009months, and 23 of 24 eligible patients (95.8%) commenced treatment. During 2023 and 2024, 85 men tested HCV PCR positive and 75 of 78 eligible patients (96%) initiated treatment. Median time from diagnosis to treatment initiation was 17\u2009days. Testing uptake remained above 90% during the subsequent 18\u2009months. HMP Berwyn achieved and sustained HCV micro\u2010elimination using a multidisciplinary model that integrated testing and treatment into routine prison healthcare. This model may be transferable to other custodial settings and populations at high\u2010risk of HCV infection.<\/jats:p>","DOI":"10.1111\/jvh.70244","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:36:26Z","timestamp":1791790586000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Model of Care Achieving Micro\u2010Elimination of Hepatitis C in the United Kingdom's Largest Prison"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3124-0041","authenticated-orcid":false,"given":"Elizabeth","family":"Hurry","sequence":"first","affiliation":[{"name":"Betsi Cadwaladr University Health Board  Bangor UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8564-1446","authenticated-orcid":false,"given":"Sarah","family":"Hulse","sequence":"additional","affiliation":[{"name":"Betsi Cadwaladr University Health Board  Bangor UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2014-5657","authenticated-orcid":false,"given":"Anya","family":"Hughes","sequence":"additional","affiliation":[{"name":"HMP Berwyn  Wrexham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_8_3_1","volume-title":"Combating Hepatitis B and C to Reach Elimination by 2030. Advocacy Brief","author":"World Health Organisation","year":"2016"},{"key":"e_1_2_8_4_1","volume-title":"Attaining the WHO Targets for Eliminating Hepatitis (B and C) as a Significant Threat to Public Health","author":"Welsh Government","year":"2017"},{"key":"e_1_2_8_5_1","volume-title":"Eliminating Hepatitis (B and C) as a Public Health Threat in Wales\u2014Actions for 2022\u201023 and 2023\u201024","author":"Welsh Government","year":"2023"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.033"},{"key":"e_1_2_8_7_1","volume-title":"Hepatitis C in England 2023: Working to Eliminate Hepatitis C as a Public Health Problem. Data to End of 2022","author":"UK Health Security Agency","year":"2024"},{"key":"e_1_2_8_8_1","volume-title":"Prison and Drugs in Europe. Current Trends and Future Challenges","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2022"},{"key":"e_1_2_8_9_1","volume-title":"Trends in the Prevention, Diagnosis and Treatment of Blood Borne Viruses in Wales: Hepatitis B, Hepatitis C and HIV Annual Report 2024 (Data to End 2023)","author":"Public Health Wales","year":"2024"},{"key":"e_1_2_8_10_1","unstructured":"cepheid.co \u201cXpert HCV VL Fingerstick \u201dhttps:\/\/www.cepheid.com\/en\u2010GB\/tests\/blood\u2010virology\u2010womens\u2010health\u2010sexual\u2010health\/xpert\u2010hcv\u2010vl\u2010fingerstick.html."},{"key":"e_1_2_8_11_1","first-page":"7977","article-title":"How We Treated More Than 100 Hepatitis C Patients at Pharmacist\u2010Led Clinics in North Wales","volume":"311","author":"Hurry E.","year":"2023","journal-title":"Pharmaceutical Journal"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riaf093.018"},{"key":"e_1_2_8_13_1","volume-title":"Trends in the Prevention, Diagnosis and Treatment of Blood Borne Viruses in Wales: Hepatitis B, Hepatitis C and HIV Annual Report 2025 (Data to End 2024)","author":"Public Health Wales","year":"2025"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(26)00014\u20102"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae471"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104873"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:36:29Z","timestamp":1791790589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/jvh.70244"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70244","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70244"}}